- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway “Dysregulated activation of the complement ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...

Researchers at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have disclosed bicyclic substituted compounds acting as complement factor B (CFB) inhibitors reported to be ...

The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. The FDA Wednesday granted an accelerated approval to Novartis’ Fabhalta in IgAN. The ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

C3G and IgAN are both rare forms of chronic kidney disease affecting the glomeruli, the kidney’s blood filters, but they arise from different immune system issues. Both conditions are immune-mediated ...